The mechanism we delineated … can be targeted at multiple levels with existing drugs, potentially improving disease outcomes in this patient population,” said Lorenzo Galluzzi, PhD.

The FDA has accepted for review the NDA for vepdegestrant to treat ESR1-mutated, ER+, HER2- advanced breast cancer.

Physician attire impacts patients' perceptions of professionalism, trust, and communication, but perceptions are highly context-dependent, research suggests.